• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of springeropenLink to Publisher's site
Acta Neuropathologica
Acta Neuropathol. Sep 2010; 120(3): 403–417.
Published online May 13, 2010. doi:  10.1007/s00401-010-0694-x
PMCID: PMC2910879

Progressive multifocal leukoencephalopathy and promyelocytic leukemia nuclear bodies: a review of clinical, neuropathological, and virological aspects of JC virus-induced demyelinating disease

Abstract

Progressive multifocal leukoencephalopathy is a fatal viral-induced demyelinating disease that was once rare but has become more prevalent today. Over the past decades, much has been learned about the disease from molecular study of the etiological agent of the disease, JC virus. Recently, promyelocytic leukemia nuclear bodies (PML-NBs), punctuate structures for important nuclear functions in eukaryotic cells, were identified as an intranuclear target of JC virus infection. Neuropathologically, JC virus-infected glial cells display diffuse amphophilic viral inclusions by hematoxylin–eosin staining (full inclusions), a diagnostic hallmark of this disease. Recent results using immunohistochemistry, however, revealed the presence of punctate viral inclusions preferentially located along the inner nuclear periphery (dot-shaped inclusions). Dot-shaped inclusions reflect the accumulation of viral progeny at PML-NBs, which may be disrupted after viral replication. Structural changes to PML-NBs have been reported for a variety of human diseases, including cancers and neurodegenerative disorders. Thus, PML-NBs may provide clues to the further pathogenesis of JC virus-induced demyelinating disease. Here, we review what we have learned since the disease entity establishment, including a look at recent progress in understanding the relationship between JC virus, etiology and PML-NBs.

Keywords: Progressive multifocal leukoencephalopathy, JC virus, Promyelocytic leukemia nuclear body (PML-NB), Full inclusions, Dot-shaped inclusions

Progressive multifocal leukoencephalopathy

History

Progressive multifocal leukoencephalopathy is a distinct neurologic entity established in 1958 [5]. Two cases of chronic lymphatic leukemia and one case of Hodgkin’s lymphoma were described as having similar clinical outcomes and sharing a characteristic neuropathology among postmortem brains. Uniquely, a mixture of small and larger demyelinating lesions was disseminated in the white matter and to a lesser degree, also in the gray matter. The small demyelinating lesions appeared to merge to form larger ones, an arrangement that was distinct from other demyelinating diseases known at that time. The fusion of multifocal demyelinating lesions was regarded as a progressive process and thus, the disease was named progressive multifocal leukoencephalopathy (Fig. 1a).

Fig. 1
Neuropathology of progressive multifocal leukoencephalopathy. a Characteristic demyelinating patterns, in which small well-demarcated lesions fuse to form larger lesions [Kluver-Barrera (KB) staining, bar 1.0 mm]. b Broad myelin pallor in the ...

The diagnostic hallmark of progressive multifocal leukoencephalopathy is the presence of oligodendrocytes with enlarged nuclei containing intranuclear amphophilic inclusions. The presence of abnormally bizarre astrocytes has been also described. A link to viral infection was suggested [19] and two independent groups subsequently revealed the presence of polyoma-like virions in round or filamentous forms by electron microscopy [121, 150]. Isolation of the virus was difficult but primary human fetal glia cells were eventually identified as the first cell culture system that could support viral propagation. Human polyomavirus isolated from autopsied brain tissue was named JC virus after the patient, Mr. John Cunningham [98]. Progressive multifocal leukoencephalopathy was rare in those days, and regarded as a “slow virus infection” of the central nervous system, similar to scrapie, Kuru, and Creutzfeldt-Jakob disease.

Clinical aspects observed over the past three decades

Progressive multifocal leukoencephalopathy develops in patients with impaired immunity. The number of reported cases of this previously rare disease has significantly increased since the 1980s due to the pandemic of acquired immunodeficiency syndrome (AIDS). In the south of Florida in the United States, for example, there was a 12-fold increase in the frequency of diagnosis in 1990–1994 when compared with 1980–1984 [8]. Introduction of highly active antiretroviral therapy (HAART), initiated in France in 1996, has significantly decreased the morbidity and mortality of AIDS [56]; however, progressive multifocal leukoencephalopathy remains a major AIDS complication resulting in death [52]. Paradoxically, some patients develop a deterioration associated with HAART treatment known as immune reconstitution inflammatory syndrome (IRIS). IRIS can result from reconstitution of the immune system to recognize pathogens/antigens, and can be accompanied by toxoplasmosis, cryptococcosis, and tuberculosis, as well as progressive multifocal leukoencephalopathy [21, 51].

In non-AIDS patients, advancements in therapy of underlying diseases and the increasing use of immunomodulatory drugs have markedly changed the clinical background. Among cases associated with lymphoproliferative disorders, Hodgkin’s disease was the most frequently reported underlying disease from 1958 to 1989; in contrast, from 1990 to 2004, more reports linked the disease to B cell chronic lymphocytic leukemia and non-Hodgkin’s lymphomas [45]. This may be in part because for the latter cases, an increasing number of patients undergo high-dose chemotherapy with hematopoietic stem cell transplantation [48, 67] or treatment with purine analogs such as fludarabine widely used since 1997 [45]. Transplant recipients of solid organs, including kidneys, livers, hearts, or lungs, can also develop demyelination, likely due to immunosuppressive treatments used to prevent graft rejection [120]. The disease can also develop in persons with rheumatic diseases related or unrelated to immunosuppressive drug treatment; indeed, systemic lupus erythematosus is one of the most common underlying diseases [15, 17, 87, 95]. In 2005, development of progressive multifocal leukoencephalopathy was reported with the use of natalizumab, a monoclonal antibody that blocks inflammatory cell entry into the brain and is used for multiple sclerosis and Crohn’s disease [70, 79, 135, 148]. Children with congenital immunodeficiency disorders [2] and the elderly (in association with age-related immunosuppression) are also at risk. Thus, progressive multifocal leukoencephalopathy is now relatively common and can develop in association with a large number of different diseases, treatments, and conditions that lead to immunodeficiency.

A diagnosis of progressive multifocal leukoencephalopathy can be indicated by radiological imaging, but detection of JC virus is essential for a definitive diagnosis. JC viral DNA can be detected in the cerebrospinal fluid by polymerase chain reaction (PCR), but negative results do not completely rule out the possibility. For example, PCR results may be negative for HAART-treated AIDS patients, due to clearance of the viral DNA associated with improved immune responses [16, 46]. Therefore, pathological examination of a biopsy or autopsy sample may be required for a final diagnosis. The clinical prognosis for progressive multifocal leukoencephalopathy is usually poor, with most cases resulting in death within 6 months, although prolonged survival has sometimes been observed [7, 8].

Neuropathology

Neuropathology of progressive multifocal leukoencephalopathy now shows histological diversity, likely associated with the expanded clinical spectrum of underlying diseases. As described earlier, the originally identified neuropathology was a typical arrangement of multiple well-demarcated demyelinating lesions, preferentially seen in the cerebral subcortical white matter [5] (Fig. 1a). However, for some recent cases, apparent cortical demyelination has been reported [11, 86, 127, 140]. The frontal lobes and parieto-occipital regions are most commonly affected, but demyelination may be also observed in deep gray structures, the cerebellum, the brainstem, and even in the spinal cord [9, 61, 62, 115].

The degree of histologically detected demyelination and of inflammation is also variable. Some cases display myelin pallor (Fig. 1b), whereas others show marked degeneration associated with axonal damage and the appearance of numerous foamy macrophages harboring phagocytolytic lipids or myelin debris. Such lesions are regarded as “burnt out,” and are often observed in cases associated with AIDS [52, 76]. A broad distribution of burnt out lesions may imply prolonged survival concurrent with advanced treatment [52]. The inflammatory response is usually poor; however, in cases of IRIS, severe inflammation may be present, including marked intraparenchymal and perivascular infiltration by macrophages and T lymphocytes [51, 85, 136].

The etiology of progressive multifocal leukoencephalopathy is JC virus lytic infection leading to the destruction of myelin sheaths. Therefore, detection of glial cells harboring JC virus inclusions is essential for pathological diagnosis. The characteristic cells are usually seen at the periphery of the demyelinating lesions, if the lesions are well demarcated (Fig. 1c). In contrast, if myelin pallor is broadly dispersed, the affected cells also tend to be scattered in a relatively broad area (Fig. 1d). The viral inclusions appear as amphophilic material dispersed throughout the nucleoplasm (full inclusions), by hematoxylin–eosin (HE) staining. However, the presence of numerous cells is also noted, which have a clearer nucleoplasm and marginated chromatin but lacking amphophilic material, despite nuclear enlargement (Fig. 1e–h). By immunohistochemistry, some of these cells display a distinct punctate distribution of promyelocytic leukemia (PML) protein, indicating the appearance of promyelocytic leukemia nuclear bodies (PML-NBs; note that for clarity, “PML” refers herein only to promyelocytic leukemia or PML protein, and not to the disease progressive multifocal leukoencephalopathy) (Fig. 1i). Both the JC viral DNA genome and viral capsid proteins show punctate signals by in situ hybridization and immunohistochemistry, respectively (dot-shaped inclusions) (Fig. 1j, k). Because PML protein and JC viral capsid proteins co-localize [117, 118] (Fig. 7), PML-NBs are likely the sites of JC viral replication. Dot-shaped inclusions are indicative of an earlier stage of viral infection, prior to the stage at which full inclusions would be observed (Fig. 1j–l).

Fig. 7
JC viral capsid proteins accumulate at PML-NBs in human brain tissue and COS-7 cells. JC virus capsid protein VP1 co-localizes in dots with the PML protein, a major component of PML-NBs. This was observed both in a human brain with progressive multifocal ...

By electron microscopy, JC virions are round or filamentous structures, approximately 35–40 nm in size. Although the intranuclear distributions of viruses are variable, many cells contain more viruses at the periphery than in center of the nucleus. Occasionally, round virions display a perfect alignment pattern, called crystalloid arrays (Fig. 2). This alignment pattern indicates that viral spread is associated with specific intranuclear structures, rather than being the result of viruses freely floating in the nucleoplasm. In 1980, Mazlo and Tariska [84] investigated the first phase of viral replication using electron microscopy and reported that viral progeny always appear in the vicinity of the inner nuclear membrane after nuclear enlargement of infected oligodendrocytes. Today, we better understand the development of intranuclear viral inclusions at a molecular level; nevertheless, even 30 years later these new findings are consistent with earlier results based on extensive ultrastructural studies.

Fig. 2
Electron micrograph of JC virions. JC virions, uniform in both size and shape display perfect alignment patterns called crystalloid arrays (Bar 1 μm). Courtesy of Drs. Shigeki Takeda and Hitoshi Takahashi

The JC virus biology and molecular pathogenesis

The human polyomavirus JC genome

JC virus has a circular double-stranded DNA genome. The complete sequence was first determined for the Mad-1 strain (5,130 bp) [41]. The first Japanese strain, Tokyo-1 (5,128 bp) was isolated [90], and we determined its complete sequence [116]. JC virus shares approximately 70% DNA sequence similarity with SV40 and BK virus, and displays a similar tripartite genome organization with early and late coding regions and a regulatory region. The early coding region encodes multifunctional regulatory proteins, large T antigen and its splicing variants (t, T′135, T′136, and T′165) [134]. The late region encodes three capsid proteins, VP1, VP2, and VP3, and a small regulatory protein called agnoprotein.

The JC viral regulatory sequence is located between the early and late coding regions, and the promoter-enhancer elements function bidirectionally. The regulatory sequence displays marked diversity, but the sequences can be roughly divided into two groups, “archetype” and “neurotropic type”. Viruses isolated from the urine of healthy individuals have consistently been found to contain a characteristic regulatory sequence known as the archetype, which is composed of five segments: 25-, 23-, 55-, 66-, 18-bp sequences (Fig. 3). In contrast, viruses isolated from demyelinating brains display divergent sequences designated as the “neurotropic type” (also referred to as the “PML-type” where “PML” means progressive multifocal leukoencephalopathy). The neurotropic type regulatory sequences appear to have arisen from the archetype via deletion and duplication. For example, in the Mad-1 sequence, the 23- and 66-bp segments are deleted, and the 25-, 55-, and 18-bp segments are duplicated, resulting in 98-bp tandem repeats. In the Tokyo-1 sequence, the 66-bp portion is largely deleted, most 55- and 18-bp segments are duplicated, with a unique 17-bp sequence insertion [83]. Sequence rearrangement from the archetype to the neurotropic type may increase restricted tissue tropism or virulence, thus affecting the overall of pathogenic potential of the virus [22]. However, it is also argued that sequence rearrangement does not change the JC virus biology [124]. The so-called “archetype hypothesis” will be described further below.

Fig. 3
JC viral regulatory sequences. The viral regulatory sequences are divergent and divided into two groups, the “archetype” and “neurotropic type.” The archetype sequence consists of five sub-sequences, 25-, 23-, 55-, 66-, ...

The archetype hypothesis

Early interest focused on the idea of “slow virus infection” and the question was frequently raised, how does JC virus persist asymptomatically but in some cases, cause opportunistic demyelinating disease? JC virus is ubiquitous in human populations and approximately 50–80% of adults present antibodies against the virus [72, 97]. Although seroprevalence continues to increase until the seventh decade of life, most individuals are thought to already have asymptomatic infections by early childhood. Primary infections may occur via respiratory inhalation [109, 113] or through consumption of contaminated food or beverages [1214]. The viruses are presumably latent or persistent in lymphoid organs such as the spleen or tonsils, as well as bone marrow, and circulate in association with peripheral lymphocytes, monocytes, or cell-free plasma [32, 33, 43, 57, 88, 133]. A small amount of virus seems to replicate in the kidney and the virus is occasionally excreted in the urine. Circulating viruses may reach the brain and if host immunity is compromised, the virus can cause progressive multifocal leukoencephalopathy.

In 1990, in what is arguably one of the most important and interesting studies in the field, the presence of the so-called archetypal viruses was advocated [147]. Archetypal viruses are frequently excreted in the urine of healthy individuals [69, 146, 147] and detected in urban sewage [14]. Thus, it seems to be the archetype that circulates in the human population. It has been proposed that subsequent to a primary infection, the archetype remains quiescent in the kidneys or other organs with occasional excretion to the urine. Some time later, the virus may transform to the neurotropic type via sequence rearrangement (in particular, deletion and duplication; see above). Neurotropic type viruses acquire neurovirulence and thus can cause progressive multifocal leukoencephalopathy (Fig. 4a).

Fig. 4
The archetype hypothesis. a Archetypal viruses are frequently detected in the urine of healthy individuals, whereas neurotropic types are detected in the brains with progressive multifocal leukoencephalopathy. Thus, the archetypal viruses, which are ubiquitous ...

Subsequent to the promotion of the archetype idea, how and where the viruses transform from the archetype to the neurotropic type became a subject of debate. If the virus is transmitted via respiratory inhalation, then it would stand to reason that the archetype would be detected in tonsilar tissues, an initial site of infection. In one report, however, viral sequences from such samples were identified as mostly of the neurotropic type [88], although archetypal sequences were detected in another study [63]. JC virus may be transmitted by consumption of contaminated food or beverages [1214] and consistent with this, JC viral sequences are frequently detectable in the human gastrointestinal (GI) tract [77, 106, 107]. However, according to one study, viral sequences detected in the GI tract were identified as belonging to the Mad-1-like neurotropic type [77]. JC virus may also circulate in the body in association with peripheral blood lymphocytes (PBLs), where sequence arrangement may occur. One study reports that the viruses in PBLs were mostly of the neurotropic type [31], and the presence of both archetype and neurotropic types was reported in another study [6]. Bone marrow has also been suggested as the site of transformation, as neurotropic type virus has been detected there as well [130]. Making the story yet more confusing, the presence of JC viral DNA has repeatedly been detected in postmortem brain tissue taken from patients who died from non-neurologic diseases [29, 36, 99, 141]. Unexpectedly, these viruses contain the rearranged, neurotropic type sequences and thus, the possibility arises that the brain is also a site of latency [29, 99, 141]. Repeated detection of neurotropic viruses in multiple organs of carrier individuals stimulated arguments against the archetype hypothesis. Importantly, pediatric patients with congenital immunosuppression display progressive multifocal leukoencephalopathy in which both archetype and neurotropic type viruses are present in different tissues. These data have been interpreted to mean that in some patients, demyelinating disease may develop after a primary infection rather than requiring a latency period [93, 94]. The archetype hypothesis has been widely accepted and indeed, the disease may occur by transformation from the archetype to neurotropic type. However, at least one alternative possibility remains, i.e. that neurotropic type viruses also circulate in normal human populations and moreover, may cause demyelinating disease upon primary infection (Fig. 4b).

Nuclear factors define JC virus neurotropism

Today, we know that JC virus infection is not specific to oligodendrocytes, as viral DNA or proteins have been repeatedly detected in multiple tissues. However, the disease-state outcome of infection, progressive multifocal leukoencephalopathy, selectively occurs in human oligodendroglias. Why JC virus establishes its most efficient lytic infection in this specific cell type and not others remains largely an open question.

The life cycle of polyomaviruses is comprised of early and late events. During early events, viral infection is initiated by attachment to a cell surface receptor, followed by trafficking from the cell membrane toward the nucleus. Next, T antigens are synthesized, and they assist replication of viral genomic DNAs in the nucleus. During late events, the viral capsid proteins VP1, VP2, and VP3 are synthesized in the cytoplasm, and they localize to the nucleus for production of viral progeny. Finally, viral progeny are released from the cells, at which time they can go onto infect additional host cells (Fig. 5a). Cellular susceptibility for lytic infection can be determined at any stage in the lytic cycle.

Fig. 5
What determines JC virus neurotropism? a The viral life cycle begins with binding to cell surface receptors and is completed by the release of progeny from the host cell. Cellular susceptibility, for efficient production of viral progeny, can be regulated ...

JC virus can bind to receptors present on a variety of cell types, but progeny production does not necessarily occur in all cell types. Viral entry is mediated by a ubiquitous receptor, an N-linked glycoprotein with α(2–6)-linked sialic acids, which associates with the serotonergic receptor 5HT2A on human glial cells [35, 81]. However, even when the virus attaches to cell surface receptors, or penetrates and reaches the nucleus, these events may not always lead to completion of the viral lytic cycle. The results of in vitro experiments demonstrated that JC virus entry into nuclei was observed for 15 different types of cell lines, but among them, virus replication occurred exclusively in human neuroblastoma cells [126]. The data indicate that the presence of cell surface receptors is essential but does not specifically determine cellular susceptibility for efficient lytic infection [34, 139] (Fig. 5b).

The 98-bp tandem repeats in the regulatory sequence of Mad-1 were found to be a transcriptional regulatory element with enhancer-like activity in human glial cells [65]. Since then, the results of many studies have supported the idea that restricted lytic infection by JC virus in human brain tissue depends on the presence of nuclear factors that are predominantly expressed in glial cells. The rearranged sequence of the regulatory regions markedly affects the levels of viral transcription and replication, as they encode binding sites for nuclear proteins that regulate viral DNA replication or transcriptional activity. The sequences include the TATA box, and binding sites for nuclear transactivators, including Sp1, YB1, sup2, NF-κB, Purα, Tst-1, c-Jun, and NF-1 (reviewed in [102]). Thus, efficient lytic infection in specific cells seems to be dependent on multiple nuclear factors that selectively bind to the rearranged regulatory sequence.

Interestingly, recent studies have revealed that JC virus also infects neurons in cerebellar granule layers and even pyramidal neurons in the cerebral cortex. In the cerebellum, lytic infection of granule cells was proposed as JCV granule cell neuronopathy, and in the cerebral cortex, fulminant JC virus encephalopathy [73, 143, 144]. These data suggest that efficient lytic infection proceeds even in neuronal cells, a process less well understood than lytic infection in glial cells.

PML-NBs as an intranuclear target for JC virus infection

Since establishment of a eukaryotic expression system to generate virus-like particles (VLPs) [119], we have been studying the molecular mechanisms underlying how JC virus develops intranuclear inclusions. The JC virus capsid would be composed of VP1, VP2, and VP3, likely in a specific ratio as in SV40 [80]. Proportional expression of the capsid proteins is in part regulated by alternative splicing, and at least four species of late RNAs are produced (M1–M4) [116]. Of these, it is M1 that encodes VP2/VP3 and M2 that encodes VP1, which is downstream of agnoprotein (Fig. 6) (note that because the complete amino acid sequence of VP3 is identical to the C-terminal two-thirds of VP2, we refer to them collectively as VP2/VP3).

Fig. 6
Structures of JC virus late RNAs. Expression of major capsid protein VP1 and minor capsid proteins VP2/VP3 is kept roughly proportional by alternative splicing. VP1 is encoded on the M2 RNA, and VP2/VP3 on M1, downstream of the agnoprotein. Diagram based ...

Nuclear proteins typically contain nuclear localization signals (NLSs), most commonly a stretch of basic amino acids such as K (lysine) and R (arginine). JC virus VP1 is inefficient in nuclear transport, which is attributable to what is presumably a weak NLS in its N-terminal sequence, MAPTKRKGERKD. This sequence has the properties of an NLS; namely, basic amino acids (K5R6K7 and R10K11) flank the intervening residues GE (superscripts indicate the positions of residues in an amino acid sequence). This can be compared with SV40 VP1, which includes the sequence MAPTKRKGSCPGAAPKKPKE (including K5R6K7 and K16K17, K19), which functions as an efficient, bipartite NLS [58]. It stands to reason, then, that with its functionally weak NLS, JC virus VP1 is distributed in both the cytoplasm and the nucleus, whereas with its efficient NLS, SV40 VP1 is exclusively localized to the nucleus. Exclusive nuclear localization of JC virus VP1 can be achieved upon co-expression with VP2/VP3, which contains two clusters of basic amino acids in the C-terminal region, GPNKKKRRK (cluster 1) and KRRSRSSRS (cluster 2). These sequences compensate for the inefficient nuclear targeting of VP1.

Interestingly, co-transported capsid proteins were found to accumulate at dot-shaped subnuclear domains preferentially detected at the nuclear periphery; that is, at PML-NBs. Confocal microscopic analysis has clearly demonstrated co-localization of VP1 with PML protein, a major component of PML-NBs. Co-localization in a dot-shaped distribution pattern was observed both in human brain tissues with progressive multifocal leukoencephalopathy and in COS-7 cells producing VLPs. In the nuclei, major and minor capsid proteins were found to stretch their intranuclear distributions along nuclear matrix-like structures (Fig. 7a, b).

By electron microscopy, along with viral gene manipulation in COS-7 cells, we have revealed that in the presence of VP2/VP3, colloidal gold particles representing the VP1 epitopes were clustered along the inner nuclear periphery, where numerous VLPs with both round and filamentous structures were also observed. The data are consistent with what has been seen for JC virus-infected glial cells in human brain (Fig. 8). Altogether, it appears that major and minor capsid proteins move cooperatively from the cytoplasm to the nucleus and then accumulate in PML-NBs, where they are assembled into progeny virions (Fig. 9).

Fig. 8
Electron micrographs of JC virions in human brain tissues and of VLPs in COS-7 cells. a In human brain tissue with progressive multifocal leukoencephalopathy, electron microscopy reveals clustered native virions of both round and filamentous structures ...
Fig. 9
Schematic illustration of late events in the JC virus life cycle. VP1 may associate with VP2/VP3, and they are co-transported to the nucleus. Complexes of VP1 and VP2/VP3 are assembled into progeny virions at PML-NBs, and likely spread throughout the ...

What is the mechanism of JC virus-mediated cell death?

The mechanisms of JC virus-mediated cell death remain largely unclear. JC virus-infected cells may undergo apoptosis [108, 145]. However, this is in contrast with another report, in which the authors suggest that JC virus-mediated cell death is a non-apoptotic, necrotic mode of death in progenitor-derived astrocyte cell culture [114]. A recent study also demonstrated higher expression of the anti-apoptotic protein survivin, and the authors claimed that viral-infected cells are anti-apoptotic, allowing for completion of the viral lytic cycle [100].

During development of full viral inclusions, PML-NBs may go on to disrupted [117, 118], and our current thinking is that disruption or even dysfunction of PML-NBs may induce JC virus-mediated cell death. Indeed, disruption or dysfunction of PML-NBs is associated with a variety of human diseases, including cancers, neurodegenerative disorders, and viral infections, as described below.

PML-NBs and human diseases

PML-NBs, also known as PML oncogenic domains or nuclear domain 10 (ND10), are dynamic, macromolecular, dot-shaped structures that are ubiquitously present in eukaryotic cells (recent reviews in [10, 20, 30, 103]). PML-NBs relate to important nuclear functions, including cell cycle regulation, DNA replication, repair, transcription, apoptosis, and senescence. PML-NBs vary both in size and in number, depending on the cell cycle phase and differentiation state of the cell, and in response to cellular stress [30, 132]. In cells cultured in vitro, PML-NBs are generally few and smallest in G0, and more numerous and larger when in S phase. PML-NBs are re-established in G1 after mitosis. PML-NBs are structurally and functionally heterogeneous, and nuclear proteins including p53, CBP/p300, Daxx, BLM, Pin1, HDAC7, and pRB traffic in and out, depending on both normal and pathological conditions. PML protein expression is frequently up-regulated in activated cells [44].

The pathogenic significance of PML-NBs was first indicated in acute promyelocytic leukemia, wherein the PML gene is fused to the retinoic acid receptor α (RARα) gene due to t(15;17) chromosomal translocation, resulting in disruption of PML-NBs [23, 47, 60]. Subsequent to this finding, the PML protein and PML-NBs were studied extensively in relation to tumorigenesis, both in basic research studies and in the clinic. PML-NBs are sites of tumor suppression, where PML protein and p53 function cooperatively [50, 111]. PML protein expression is reduced or abolished in human cancers of various histologic origins, including prostate, colon, breast, lung, lymphomas, CNS tumors, and germ cell tumors [53]. Interestingly, PML-NBs interact with particularly gene-rich and transcriptionally active regions of chromatin, including the TP53 locus that encodes p53 [125]. Therefore, the PML protein as well as PML-NBs has significant functions for tumor suppression, especially as associated with p53. Thus, their dysfunction or disruption likely relate to both oncogenesis and tumor progression.

Polyglutamine diseases such as Huntington’s disease and spinocerebellar ataxias are neurological diseases characterized by genetic mutations of expanded CAG repeats that encode polyglutamines (polyQ). The mutant proteins with expanded polyQ tracts accumulate in the nucleus and form neuronal intranuclear inclusions (NIIs). NIIs are frequently associated with PML-NBs [128, 129]. The results of in vitro experiments show that the matrix-associated PML-NB structures are disrupted by polyQ mutant proteins [64, 123]. Thus, the presence of NIIs may cause disordered nuclear functions, such as altered or impaired transcription, as well as induce cell death or degeneration of neuronal cells [42, 96]. Moreover, much interest has been focused on understanding the role of PML-NBs in protein storage and ubiquitin-mediated degradation by proteasomes [59, 92]. A model was proposed wherein PML-NBs scan the nucleus in search of misfolded proteins and promote degradation of these errant proteins via the proteasome. However, it is not yet clear if the presence of NIIs is pernicious, coincidental, or beneficial for neuronal cells [71, 112, 122].

A variety of viruses target PML-NBs, including herpes simplex virus type-1 (HSV-1), human cytomegalovirus (HCMV), Epstein–Barr virus (EBV), papillomaviruses, and polyomaviruses. These viruses may alter components of PML-NBs, regulate expression and localization of PML protein, and even disrupt PML-NB structure (recent review in [131]). For example, HSV-1, HCMV, and EBV all disrupt PML-NBs during early events of viral replication, whereas human papillomavirus type 33 (HPV33) reorganizes PML-NB components and utilizes them for efficient capsid assembly during late events [39, 40]. Expression of PML protein is up-regulated after treatment with interferon (IFN), suggesting that PML-NBs would be an anti-viral structure [38]. Recent data, however, also indicate that PML-NBs are at least in part pro-viral, and facilitate latency in HSV-1 and HCMV infection [110]. As we understand it today, progressive multifocal leukoencephalopathy is a JC virus-induced demyelinating disorder of the nervous system, in which PML-NBs are the targets for viral infection. How PML-NBs are involved in or utilized for JC virus infection is the next issue that will be addressed (Fig. 10a).

Fig. 10
Does JC virus induce brain tumors in humans? a PML-NBs are the sites of multiple nuclear functions, and disruption or dysfunction of PML-NBs can cause a variety of human diseases, including leukemia and other cancers, as well as neurodegenerative disorders. ...

Does JC virus induce brain tumors in humans?

Finally, we reconsider a long-lasting question asked since the discovery of JC virus, Can JC virus induce brain tumors in humans? This question has been raised many times, as the virus-induced brain tumors in experimental animals, and viral DNA or proteins were repeatedly detected in human tumor tissue (reviewed in [66, 104, 142] and others). In 1970s, it was shown that JC virus inoculated into experimental animals can induce brain tumors [82, 137]. The JC virus Tokyo-1 strain was shown to induce medulloblastoma in hamsters [91]. Indeed, JC virus was highly oncogenic and capable of inducing various types of brain tumors in these animals, including glioblastomas, medulloblastomas, neuroblastomas, pineocytomas, and/or other tumors of central nervous system. In 1999 and 2000, transgenic mice were generated in which the early regions of the archetype or neurotropic type are presented, and both were capable of inducing medulloblastoma/primitive neuroectodermal tumor (PNET) and pituitary neoplasia [49, 75]. Thus, there is no doubt in that JC virus is oncogenic to experimental animals.

From the late 1990s to the early 2000s, a number of reports described detection of JC virus, a viral DNA genome or oncogenic T antigen, in human clinical samples. JC virus has been detected in brain tumors of different histological types, including medulloblastoma, astrocytoma, oligodendroglioma, oligoastrocytoma, anaplastic astrocytoma, anaplastic oligodendroglioma, glioblastoma, ependymoma, and primary CNS lymphoma [18, 2427, 74, 105]. The virus has also been detected in colorectal, gastric and esophageal cancers, and even in lung cancers [1, 28, 37, 77, 89, 107, 149]. However, it is difficult to know if the virus is causative for human tumors, as JC virus is ubiquitously prevalent in the human population and has been detected in multiple tissues, including the unaffected brains, as described earlier. In addition, some groups have reported discordant results suggesting that JC virus is unlikely to be linked to oncogenesis in medulloblastoma or PNET [54, 68, 138], and in oligodendroglioma or astrocytoma [55]. Thus, it is not yet clear if JC virus infection causes malignant tumors in humans.

In progressive multifocal leukoencephalopathy, the glial cells with enlarging nuclei seem markedly activated in their cell cycle, with distinct expression of MIB-1 (Ki-67), proliferating cell nuclear antigen (PCNA), cyclin A and cyclin B1 [3, 4, 78]. The results of microarray analysis also demonstrate enhanced transcription of the cyclin A and B1 genes [101]. Despite relatively high MIB-1 expression, however, mitotic figures have not been observed. Thus, JC virus likely first activates host cells in their cell cycle, which is presumably advantageous for viral progeny production, but before completion, the cycle is dysregulated or blocked. To address the persisting question if JC virus can induce malignant tumors in humans, it might be useful to clarify how cell fate is determined in infected cells and separated into lytic infection versus malignant transformation. We expect that studies on PML-NBs might provide interesting clues that could increase our understanding in the future (Fig. 10b).

Conclusions

Neuropathology of progressive multifocal leukoencephalopathy has diverged with the expanded clinical spectrum of underlying diseases. Nevertheless, studies on JC virus biology have advanced our understanding of this demyelinating disorder. Nuclear viral inclusions in the form of either full inclusions or dot-shaped inclusions are present in the enlarged nuclei of glial cells, and PML-NBs have been identified as an intranuclear target of JC virus infection. We hope future studies on PML-NBs may provide clues as to how fate is determined in JC virus-infected cells, as well as insight into JC virus-mediated lytic infection or malignant transformation.

Acknowledgments

I thank all of my past and present colleagues and collaborators. Special thanks to Drs. Toshiki Uchihara (Tokyo Metropolitan Institute of Neuroscience) and Hidehiro Mizusawa (Tokyo Medical and Dental University). This work, as well as some of the original research studies discussed herein, was supported by grants for Research on Measures for Intractable Diseases (Prion Disease and Slow Virus Infection) from the Ministry of Health, Labour and Welfare of Japan.

Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

References

1. Abdel-Aziz HO, Murai Y, Hong M, et al. Detection of the JC virus genome in lung cancers: possible role of the T-antigen in lung oncogenesis. Appl Immunohistochem Mol Morphol. 2007;15:394–400. doi: 10.1097/01.pai.0000213126.96590.64. [PubMed] [Cross Ref]
2. Angelini L, Pietrogrande MC, Delle Piane MR, et al. Progressive multifocal leukoencephalopathy in a child with hyperimmunoglobulin E recurrent infection syndrome and review of the literature. Neuropediatrics. 2001;32:250–255. doi: 10.1055/s-2001-19119. [PubMed] [Cross Ref]
3. Ariza A, Mate JL, Fernandez-Vasalo A, et al. p53 and proliferating cell nuclear antigen expression in JC virus-infected cells of progressive multifocal leukoencephalopathy. Hum Pathol. 1994;25:1341–1345. doi: 10.1016/0046-8177(94)90095-7. [PubMed] [Cross Ref]
4. Ariza A, Mate JL, Isamat M, Calatrava A, Fernandez-Vasalo A, Navas-Palacios JJ. Overexpression of Ki-67 and cyclins A and B1 in JC virus-infected cells of progressive multifocal leukoencephalopathy. J Neuropathol Exp Neurol. 1998;57:226–230. doi: 10.1097/00005072-199803000-00003. [PubMed] [Cross Ref]
5. Astrom KE, Mancall EL, Richardson EP., Jr Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin’s disease. Brain. 1958;81:93–111. doi: 10.1093/brain/81.1.93. [PubMed] [Cross Ref]
6. Azzi A, Santis R, Ciappi S, et al. Human polyomaviruses DNA detection in peripheral blood leukocytes from immunocompetent and immunocompromised individuals. J Neurovirol. 1996;2:411–416. doi: 10.3109/13550289609146907. [PubMed] [Cross Ref]
7. Berger JR. Progressive multifocal leukoencephalopathy. Curr Neurol Neurosci Rep. 2007;7:461–469. doi: 10.1007/s11910-007-0072-9. [PubMed] [Cross Ref]
8. Berger JR, Pall L, Lanska D, Whiteman M. Progressive multifocal leukoencephalopathy in patients with HIV infection. J Neurovirol. 1998;4:59–68. doi: 10.3109/13550289809113482. [PubMed] [Cross Ref]
9. Bernal-Cano F, Joseph JT, Koralnik IJ. Spinal cord lesions of progressive multifocal leukoencephalopathy in an acquired immunodeficiency syndrome patient. J Neurovirol. 2007;13:474–476. doi: 10.1080/13550280701469178. [PubMed] [Cross Ref]
10. Bernardi R, Pandolfi PP. Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat Rev Mol Cell Biol. 2007;8:1006–1016. doi: 10.1038/nrm2277. [PubMed] [Cross Ref]
11. Bienfait HP, Louwerse ES, Portegies P, Meer JT. Progressive multifocal leukoencephalopathy presenting as a solitary gray matter lesion. J Neurol. 1998;245:557–558. doi: 10.1007/s004150050243. [PubMed] [Cross Ref]
12. Bofill-Mas S, Clemente-Casares P, Major EO, Curfman B, Girones R. Analysis of the excreted JC virus strains and their potential oral transmission. J Neurovirol. 2003;9:498–507. [PubMed]
13. Bofill-Mas S, Formiga-Cruz M, Clemente-Casares P, Calafell F, Girones R. Potential transmission of human polyomaviruses through the gastrointestinal tract after exposure to virions or viral DNA. J Virol. 2001;75:10290–10299. doi: 10.1128/JVI.75.21.10290-10299.2001. [PMC free article] [PubMed] [Cross Ref]
14. Bofill-Mas S, Girones R. Excretion and transmission of JCV in human populations. J Neurovirol. 2001;7:345–349. doi: 10.1080/13550280152537210. [PubMed] [Cross Ref]
15. Boren EJ, Cheema GS, Naguwa SM, Ansari AA, Gershwin ME. The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases. J Autoimmun. 2008;30:90–98. doi: 10.1016/j.jaut.2007.11.013. [PubMed] [Cross Ref]
16. Bossolasco S, Calori G, Moretti F, et al. Prognostic significance of JC virus DNA levels in cerebrospinal fluid of patients with HIV-associated progressive multifocal leukoencephalopathy. Clin Infect Dis. 2005;40:738–744. doi: 10.1086/427698. [PubMed] [Cross Ref]
17. Calabrese LH, Molloy ES, Huang D, Ransohoff RM. Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease. Arthritis Rheum. 2007;56:2116–2128. doi: 10.1002/art.22657. [PubMed] [Cross Ref]
18. Caldarelli-Stefano R, Boldorini R, Monga G, Meraviglia E, Zorini EO, Ferrante P. JC virus in human glial-derived tumors. Hum Pathol. 2000;31:394–395. doi: 10.1016/S0046-8177(00)80256-7. [PubMed] [Cross Ref]
19. Cavanagh JB, Greenbaum D, Marshall AH, Rubinstein LJ. Cerebral demyelination associated with disorders of the reticuloendothelial system. Lancet. 1959;2:524–529. doi: 10.1016/S0140-6736(59)91774-X. [PubMed] [Cross Ref]
20. Ching RW, Dellaire G, Eskiw CH, Bazett-Jones DP. PML bodies: a meeting place for genomic loci? J Cell Sci. 2005;118:847–854. doi: 10.1242/jcs.01700. [PubMed] [Cross Ref]
21. Cinque P, Bossolasco S, Brambilla AM, et al. The effect of highly active antiretroviral therapy-induced immune reconstitution on development and outcome of progressive multifocal leukoencephalopathy: study of 43 cases with review of the literature. J Neurovirol. 2003;9(Suppl 1):73–80. [PubMed]
22. Daniel AM, Swenson JJ, Mayreddy RP, Khalili K, Frisque RJ. Sequences within the early and late promoters of archetype JC virus restrict viral DNA replication and infectivity. Virology. 1996;216:90–101. doi: 10.1006/viro.1996.0037. [PubMed] [Cross Ref]
23. The H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell. 1991;66:675–684. doi: 10.1016/0092-8674(91)90113-D. [PubMed] [Cross Ref]
24. Del Valle L, Delbue S, Gordon J, et al. Expression of JC virus T-antigen in a patient with MS and glioblastoma multiforme. Neurology. 2002;58:895–900. [PubMed]
25. Del Valle L, Enam S, Lara C, Miklossy J, Khalili K, Gordon J. Primary central nervous system lymphoma expressing the human neurotropic polyomavirus, JC virus, genome. J Virol. 2004;78:3462–3469. doi: 10.1128/JVI.78.7.3462-3469.2004. [PMC free article] [PubMed] [Cross Ref]
26. Del Valle L, Gordon J, Assimakopoulou M, et al. Detection of JC virus DNA sequences and expression of the viral regulatory protein T-antigen in tumors of the central nervous system. Cancer Res. 2001;61:4287–4293. [PubMed]
27. Del Valle L, Gordon J, Enam S, et al. Expression of human neurotropic polyomavirus JCV late gene product agnoprotein in human medulloblastoma. J Natl Cancer Inst. 2002;94:267–273. [PubMed]
28. Del Valle L, White MK, Enam S, et al. Detection of JC virus DNA sequences and expression of viral T antigen and agnoprotein in esophageal carcinoma. Cancer. 2005;103:516–527. doi: 10.1002/cncr.20806. [PubMed] [Cross Ref]
29. Delbue S, Branchetti E, Boldorini R, et al. Presence and expression of JCV early gene large T Antigen in the brains of immunocompromised and immunocompetent individuals. J Med Virol. 2008;80:2147–2152. doi: 10.1002/jmv.21313. [PMC free article] [PubMed] [Cross Ref]
30. Dellaire G, Bazett-Jones DP. PML nuclear bodies: dynamic sensors of DNA damage and cellular stress. Bioessays. 2004;26:963–977. doi: 10.1002/bies.20089. [PubMed] [Cross Ref]
31. Dorries K, Vogel E, Gunther S, Czub S. Infection of human polyomaviruses JC and BK in peripheral blood leukocytes from immunocompetent individuals. Virology. 1994;198:59–70. doi: 10.1006/viro.1994.1008. [PubMed] [Cross Ref]
32. Dubois V, Dutronc H, Lafon ME, et al. Latency and reactivation of JC virus in peripheral blood of human immunodeficiency virus type 1-infected patients. J Clin Microbiol. 1997;35:2288–2292. [PMC free article] [PubMed]
33. Dubois V, Lafon ME, Ragnaud JM, et al. Detection of JC virus DNA in the peripheral blood leukocytes of HIV-infected patients. Aids. 1996;10:353–358. doi: 10.1097/00002030-199604000-00001. [PubMed] [Cross Ref]
34. Eash S, Tavares R, Stopa EG, Robbins SH, Brossay L, Atwood WJ. Differential distribution of the JC virus receptor-type sialic acid in normal human tissues. Am J Pathol. 2004;164:419–428. [PMC free article] [PubMed]
35. Elphick GF, Querbes W, Jordan JA, et al. The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science. 2004;306:1380–1383. doi: 10.1126/science.1103492. [PubMed] [Cross Ref]
36. Elsner C, Dorries K. Evidence of human polyomavirus BK and JC infection in normal brain tissue. Virology. 1992;191:72–80. doi: 10.1016/0042-6822(92)90167-N. [PubMed] [Cross Ref]
37. Enam S, Del Valle L, Lara C, et al. Association of human polyomavirus JCV with colon cancer: evidence for interaction of viral T-antigen and beta-catenin. Cancer Res. 2002;62:7093–7101. [PubMed]
38. Everett RD, Chelbi-Alix MK. PML and PML nuclear bodies: implications in antiviral defence. Biochimie. 2007;89:819–830. doi: 10.1016/j.biochi.2007.01.004. [PubMed] [Cross Ref]
39. Florin L, Sapp C, Streeck RE, Sapp M. Assembly and translocation of papillomavirus capsid proteins. J Virol. 2002;76:10009–10014. doi: 10.1128/JVI.76.19.10009-10014.2002. [PMC free article] [PubMed] [Cross Ref]
40. Florin L, Schafer F, Sotlar K, Streeck RE, Sapp M. Reorganization of nuclear domain 10 induced by papillomavirus capsid protein l2. Virology. 2002;295:97–107. doi: 10.1006/viro.2002.1360. [PubMed] [Cross Ref]
41. Frisque RJ, Bream GL, Cannella MT. Human polyomavirus JC virus genome. J Virol. 1984;51:458–469. [PMC free article] [PubMed]
42. Fu L, Gao YS, Sztul E. Transcriptional repression and cell death induced by nuclear aggregates of non-polyglutamine protein. Neurobiol Dis. 2005;20:656–665. doi: 10.1016/j.nbd.2005.05.015. [PMC free article] [PubMed] [Cross Ref]
43. Gallia GL, Houff SA, Major EO, Khalili K. Review: JC virus infection of lymphocytes—revisited. J Infect Dis. 1997;176:1603–1609. doi: 10.1086/514161. [PubMed] [Cross Ref]
44. Gambacorta M, Flenghi L, Fagioli M, et al. Heterogeneous nuclear expression of the promyelocytic leukemia (PML) protein in normal and neoplastic human tissues. Am J Pathol. 1996;149:2023–2035. [PMC free article] [PubMed]
45. Garcia-Suarez J, Miguel D, Krsnik I, Banas H, Arribas I, Burgaleta C. Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies. Am J Hematol. 2005;80:271–281. doi: 10.1002/ajh.20492. [PubMed] [Cross Ref]
46. Giudici B, Vaz B, Bossolasco S, et al. Highly active antiretroviral therapy and progressive multifocal leukoencephalopathy: effects on cerebrospinal fluid markers of JC virus replication and immune response. Clin Infect Dis. 2000;30:95–99. doi: 10.1086/313598. [PubMed] [Cross Ref]
47. Goddard AD, Borrow J, Freemont PS, Solomon E. Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia. Science. 1991;254:1371–1374. doi: 10.1126/science.1720570. [PubMed] [Cross Ref]
48. Goldberg SL, Pecora AL, Alter RS, et al. Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood. 2002;99:1486–1488. doi: 10.1182/blood.V99.4.1486. [PubMed] [Cross Ref]
49. Gordon J, Del Valle L, Otte J, Khalili K. Pituitary neoplasia induced by expression of human neurotropic polyomavirus, JCV, early genome in transgenic mice. Oncogene. 2000;19:4840–4846. doi: 10.1038/sj.onc.1203849. [PubMed] [Cross Ref]
50. Gottifredi V, Prives C. P53 and PML: new partners in tumor suppression. Trends Cell Biol. 2001;11:184–187. doi: 10.1016/S0962-8924(01)01983-3. [PubMed] [Cross Ref]
51. Gray F, Bazille C, Adle-Biassette H, Mikol J, Moulignier A, Scaravilli F. Central nervous system immune reconstitution disease in acquired immunodeficiency syndrome patients receiving highly active antiretroviral treatment. J Neurovirol. 2005;11(Suppl 3):16–22. doi: 10.1080/13550280500511741. [PubMed] [Cross Ref]
52. Gray F, Chretien F, Vallat-Decouvelaere AV, Scaravilli F. The changing pattern of HIV neuropathology in the HAART era. J Neuropathol Exp Neurol. 2003;62:429–440. [PubMed]
53. Gurrieri C, Capodieci P, Bernardi R, et al. Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J Natl Cancer Inst. 2004;96:269–279. doi: 10.1093/jnci/djh043. [PubMed] [Cross Ref]
54. Hayashi H, Endo S, Suzuki S, et al. JC virus large T protein transforms rodent cells but is not involved in human medulloblastoma. Neuropathology. 2001;21:129–137. doi: 10.1046/j.1440-1789.2001.00384.x. [PubMed] [Cross Ref]
55. Herbarth B, Meissner H, Westphal M, Wegner M. Absence of polyomavirus JC in glial brain tumors and glioma-derived cell lines. Glia. 1998;22:415–420. doi: 10.1002/(SICI)1098-1136(199804)22:4<415::AID-GLIA11>3.0.CO;2-Z. [PubMed] [Cross Ref]
56. Hogg RS, O’Shaughnessy MV, Gataric N, et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet. 1997;349:1294. doi: 10.1016/S0140-6736(05)62505-6. [PubMed] [Cross Ref]
57. Houff SA, Major EO, Katz DA, et al. Involvement of JC virus-infected mononuclear cells from the bone marrow and spleen in the pathogenesis of progressive multifocal leukoencephalopathy. N Engl J Med. 1988;318:301–305. [PubMed]
58. Ishii N, Minami N, Chen EY, Medina AL, Chico MM, Kasamatsu H. Analysis of a nuclear localization signal of simian virus 40 major capsid protein Vp1. J Virol. 1996;70:1317–1322. [PMC free article] [PubMed]
59. Janer A, Martin E, Muriel MP, et al. PML clastosomes prevent nuclear accumulation of mutant ataxin-7 and other polyglutamine proteins. J Cell Biol. 2006;174:65–76. doi: 10.1083/jcb.200511045. [PMC free article] [PubMed] [Cross Ref]
60. Kakizuka A, Miller WH, Jr, Umesono K, et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell. 1991;66:663–674. doi: 10.1016/0092-8674(91)90112-C. [PubMed] [Cross Ref]
61. Kastrup O, Maschke M, Diener HC, Wanke I. Progressive multifocal leukoencephalopathy limited to the brain stem. Neuroradiology. 2002;44:227–229. doi: 10.1007/s00234-001-0714-6. [PubMed] [Cross Ref]
62. Kastrup O, Wanke I, Esser S, Maschke M. Evolution of purely infratentorial PML under HAART: negative outcome under rapid immune reconstitution. Clin Neurol Neurosurg. 2005;107:509–513. doi: 10.1016/j.clineuro.2004.10.005. [PubMed] [Cross Ref]
63. Kato A, Kitamura T, Takasaka T, et al. Detection of the archetypal regulatory region of JC virus from the tonsil tissue of patients with tonsillitis and tonsilar hypertrophy. J Neurovirol. 2004;10:244–249. doi: 10.1080/13550280490468663. [PubMed] [Cross Ref]
64. Kaytor MD, Duvick LA, Skinner PJ, Koob MD, Ranum LP, Orr HT. Nuclear localization of the spinocerebellar ataxia type 7 protein, ataxin-7. Hum Mol Genet. 1999;8:1657–1664. doi: 10.1093/hmg/8.9.1657. [PubMed] [Cross Ref]
65. Kenney S, Natarajan V, Strike D, Khoury G, Salzman NP. JC virus enhancer-promoter active in human brain cells. Science. 1984;226:1337–1339. doi: 10.1126/science.6095453. [PubMed] [Cross Ref]
66. Khalili K, Del Valle L, Otte J, Weaver M, Gordon J. Human neurotropic polyomavirus, JCV, and its role in carcinogenesis. Oncogene. 2003;22:5181–5191. doi: 10.1038/sj.onc.1206559. [PubMed] [Cross Ref]
67. Kharfan-Dabaja MA, Ayala E, Greene J, Rojiani A, Murtagh FR, Anasetti C. Two cases of progressive multifocal leukoencephalopathy after allogeneic hematopoietic cell transplantation and a review of the literature. Bone Marrow Transplant. 2007;39:101–107. doi: 10.1038/sj.bmt.1705548. [PubMed] [Cross Ref]
68. Kim JY, Koralnik IJ, LeFave M, Segal RA, Pfister LA, Pomeroy SL. Medulloblastomas and primitive neuroectodermal tumors rarely contain polyomavirus DNA sequences. Neuro Oncol. 2002;4:165–170. doi: 10.1215/15228517-4-3-165. [PMC free article] [PubMed] [Cross Ref]
69. Kitamura T, Aso Y, Kuniyoshi N, Hara K, Yogo Y. High incidence of urinary JC virus excretion in nonimmunosuppressed older patients. J Infect Dis. 1990;161:1128–1133. [PubMed]
70. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med. 2005;353:369–374. doi: 10.1056/NEJMoa051782. [PubMed] [Cross Ref]
71. Klement IA, Skinner PJ, Kaytor MD, et al. Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice. Cell. 1998;95:41–53. doi: 10.1016/S0092-8674(00)81781-X. [PubMed] [Cross Ref]
72. Knowles WA, Pipkin P, Andrews N, et al. Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol. 2003;71:115–123. doi: 10.1002/jmv.10450. [PubMed] [Cross Ref]
73. Koralnik IJ, Wuthrich C, Dang X, et al. JC virus granule cell neuronopathy: a novel clinical syndrome distinct from progressive multifocal leukoencephalopathy. Ann Neurol. 2005;57:576–580. doi: 10.1002/ana.20431. [PubMed] [Cross Ref]
74. Krynska B, Del Valle L, Croul S, et al. Detection of human neurotropic JC virus DNA sequence and expression of the viral oncogenic protein in pediatric medulloblastomas. Proc Natl Acad Sci USA. 1999;96:11519–11524. doi: 10.1073/pnas.96.20.11519. [PMC free article] [PubMed] [Cross Ref]
75. Krynska B, Otte J, Franks R, Khalili K, Croul S. Human ubiquitous JCV(CY) T-antigen gene induces brain tumors in experimental animals. Oncogene. 1999;18:39–46. doi: 10.1038/sj.onc.1202278. [PubMed] [Cross Ref]
76. Kuchelmeister K, Gullotta F, Bergmann M, Angeli G, Masini T. Progressive multifocal leukoencephalopathy (PML) in the acquired immunodeficiency syndrome (AIDS). A neuropathological autopsy study of 21 cases. Pathol Res Pract. 1993;189:163–173. [PubMed]
77. Laghi L, Randolph AE, Chauhan DP, et al. JC virus DNA is present in the mucosa of the human colon and in colorectal cancers. Proc Natl Acad Sci USA. 1999;96:7484–7489. doi: 10.1073/pnas.96.13.7484. [PMC free article] [PubMed] [Cross Ref]
78. Lammie GA, Beckett A, Courtney R, Scaravilli F. An immunohistochemical study of p53 and proliferating cell nuclear antigen expression in progressive multifocal leukoencephalopathy. Acta Neuropathol. 1994;88:465–471. doi: 10.1007/BF00389500. [PubMed] [Cross Ref]
79. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med. 2005;353:375–381. doi: 10.1056/NEJMoa051847. [PubMed] [Cross Ref]
80. Liddington RC, Yan Y, Moulai J, Sahli R, Benjamin TL, Harrison SC. Structure of simian virus 40 at 3.8-A resolution. Nature. 1991;354:278–284. doi: 10.1038/354278a0. [PubMed] [Cross Ref]
81. Liu CK, Wei G, Atwood WJ. Infection of glial cells by the human polyomavirus JC is mediated by an N-linked glycoprotein containing terminal alpha(2–6)-linked sialic acids. J Virol. 1998;72:4643–4649. [PMC free article] [PubMed]
82. London WT, Houff SA, Madden DL, et al. Brain tumors in owl monkeys inoculated with a human polyomavirus (JC virus) Science. 1978;201:1246–1249. doi: 10.1126/science.211583. [PubMed] [Cross Ref]
83. Matsuda M, Jona M, Yasui K, Nagashima K. Genetic characterization of JC virus Tokyo-1 strain, a variant oncogenic in rodents. Virus Res. 1987;7:159–168. doi: 10.1016/0168-1702(87)90077-3. [PubMed] [Cross Ref]
84. Mazlo M, Tariska I. Morphological demonstration of the first phase of polyomavirus replication in oligodendroglia cells of human brain in progressive multifocal leukoencephalopathy (PML) Acta Neuropathol. 1980;49:133–143. doi: 10.1007/BF00690753. [PubMed] [Cross Ref]
85. Miralles P, Berenguer J, Lacruz C, et al. Inflammatory reactions in progressive multifocal leukoencephalopathy after highly active antiretroviral therapy. Aids. 2001;15:1900–1902. doi: 10.1097/00002030-200109280-00028. [PubMed] [Cross Ref]
86. Moll NM, Rietsch AM, Ransohoff AJ, et al. Cortical demyelination in PML and MS: similarities and differences. Neurology. 2008;70:336–343. doi: 10.1212/01.wnl.0000284601.54436.e4. [PubMed] [Cross Ref]
87. Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk? Autoimmun Rev. 2008;8:144–146. doi: 10.1016/j.autrev.2008.07.006. [PubMed] [Cross Ref]
88. Monaco MC, Jensen PN, Hou J, Durham LC, Major EO. Detection of JC virus DNA in human tonsil tissue: evidence for site of initial viral infection. J Virol. 1998;72:9918–9923. [PMC free article] [PubMed]
89. Murai Y, Zheng HC, Abdel Aziz HO, et al. High JC virus load in gastric cancer and adjacent non-cancerous mucosa. Cancer Sci. 2007;98:25–31. doi: 10.1111/j.1349-7006.2006.00354.x. [PubMed] [Cross Ref]
90. Nagashima K, Yamaguchi K, Yasui K, Ogiwara H. Progressive multifocal leukoencephalopathy. Neuropathology and virus isolation. Acta Pathol Jpn. 1981;31:953–961. [PubMed]
91. Nagashima K, Yasui K, Kimura J, Washizu M, Yamaguchi K, Mori W. Induction of brain tumors by a newly isolated JC virus (Tokyo-1 strain) Am J Pathol. 1984;116:455–463. [PMC free article] [PubMed]
92. Negorev D, Maul GG. Cellular proteins localized at and interacting within ND10/PML nuclear bodies/PODs suggest functions of a nuclear depot. Oncogene. 2001;20:7234–7242. doi: 10.1038/sj.onc.1204764. [PubMed] [Cross Ref]
93. Newman JT, Frisque RJ. Detection of archetype and rearranged variants of JC virus in multiple tissues from a pediatric PML patient. J Med Virol. 1997;52:243–252. doi: 10.1002/(SICI)1096-9071(199707)52:3<243::AID-JMV2>3.0.CO;2-2. [PubMed] [Cross Ref]
94. Newman JT, Frisque RJ. Identification of JC virus variants in multiple tissues of pediatric and adult PML patients. J Med Virol. 1999;58:79–86. doi: 10.1002/(SICI)1096-9071(199905)58:1<79::AID-JMV13>3.0.CO;2-V. [PubMed] [Cross Ref]
95. Nived O, Bengtsson AA, Jonsen A, Sturfelt G. Progressive multifocal leukoencephalopathy: the importance of early diagnosis illustrated in four cases. Lupus. 2008;17:1036–1041. doi: 10.1177/0961203308089445. [PubMed] [Cross Ref]
96. Okazawa H. Polyglutamine diseases: a transcription disorder? Cell Mol Life Sci. 2003;60:1427–1439. doi: 10.1007/s00018-003-3013-z. [PubMed] [Cross Ref]
97. Padgett BL, Walker DL. Prevalence of antibodies in human sera against JC virus, an isolate from a case of progressive multifocal leukoencephalopathy. J Infect Dis. 1973;127:467–470. [PubMed]
98. Padgett BL, Walker DL, ZuRhein GM, Eckroade RJ, Dessel BH. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet. 1971;1:1257–1260. doi: 10.1016/S0140-6736(71)91777-6. [PubMed] [Cross Ref]
99. Perez-Liz G, Del Valle L, Gentilella A, Croul S, Khalili K. Detection of JC virus DNA fragments but not proteins in normal brain tissue. Ann Neurol. 2008;64:379–387. doi: 10.1002/ana.21443. [PMC free article] [PubMed] [Cross Ref]
100. Pina-Oviedo S, Urbanska K, Radhakrishnan S, et al. Effects of JC virus infection on anti-apoptotic protein survivin in progressive multifocal leukoencephalopathy. Am J Pathol. 2007;170:1291–1304. doi: 10.2353/ajpath.2007.060689. [PMC free article] [PubMed] [Cross Ref]
101. Radhakrishnan S, Otte J, Enam S, Del Valle L, Khalili K, Gordon J. JC virus-induced changes in cellular gene expression in primary human astrocytes. J Virol. 2003;77:10638–10644. doi: 10.1128/JVI.77.19.10638-10644.2003. [PMC free article] [PubMed] [Cross Ref]
102. Ravichandran V, Major EO. Viral proteomics: a promising approach for understanding JC virus tropism. Proteomics. 2006;6:5628–5636. doi: 10.1002/pmic.200600261. [PubMed] [Cross Ref]
103. Reineke EL, Kao HY. Targeting promyelocytic leukemia protein: a means to regulating PML nuclear bodies. Int J Biol Sci. 2009;5:366–376. [PMC free article] [PubMed]
104. Reiss K, Khalili K. Viruses and cancer: lessons from the human polyomavirus, JCV. Oncogene. 2003;22:6517–6523. doi: 10.1038/sj.onc.1206959. [PubMed] [Cross Ref]
105. Rencic A, Gordon J, Otte J, et al. Detection of JC virus DNA sequence and expression of the viral oncoprotein, tumor antigen, in brain of immunocompetent patient with oligoastrocytoma. Proc Natl Acad Sci USA. 1996;93:7352–7357. doi: 10.1073/pnas.93.14.7352. [PMC free article] [PubMed] [Cross Ref]
106. Ricciardiello L, Chang DK, Laghi L, Goel A, Chang CL, Boland CR. Mad-1 is the exclusive JC virus strain present in the human colon, and its transcriptional control region has a deleted 98-base-pair sequence in colon cancer tissues. J Virol. 2001;75:1996–2001. doi: 10.1128/JVI.75.4.1996-2001.2001. [PMC free article] [PubMed] [Cross Ref]
107. Ricciardiello L, Laghi L, Ramamirtham P, et al. JC virus DNA sequences are frequently present in the human upper and lower gastrointestinal tract. Gastroenterology. 2000;119:1228–1235. doi: 10.1053/gast.2000.19269. [PubMed] [Cross Ref]
108. Richardson-Burns SM, Kleinschmidt-DeMasters BK, DeBiasi RL, Tyler KL. Progressive multifocal leukoencephalopathy and apoptosis of infected oligodendrocytes in the central nervous system of patients with and without AIDS. Arch Neurol. 2002;59:1930–1936. doi: 10.1001/archneur.59.12.1930. [PubMed] [Cross Ref]
109. Sabath BF, Major EO. Traffic of JC virus from sites of initial infection to the brain: the path to progressive multifocal leukoencephalopathy. J Infect Dis. 2002;186(Suppl 2):S180–S186. doi: 10.1086/344280. [PubMed] [Cross Ref]
110. Saffert RT, Kalejta RF. Promyelocytic leukemia-nuclear body proteins: herpesvirus enemies, accomplices, or both? Future Virol. 2008;3:265–277. doi: 10.2217/17460794.3.3.265. [PMC free article] [PubMed] [Cross Ref]
111. Salomoni P, Pandolfi PP. The role of PML in tumor suppression. Cell. 2002;108:165–170. doi: 10.1016/S0092-8674(02)00626-8. [PubMed] [Cross Ref]
112. Saudou F, Finkbeiner S, Devys D, Greenberg ME. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell. 1998;95:55–66. doi: 10.1016/S0092-8674(00)81782-1. [PubMed] [Cross Ref]
113. Seth P, Diaz F, Major EO. Advances in the biology of JC virus and induction of progressive multifocal leukoencephalopathy. J Neurovirol. 2003;9:236–246. [PubMed]
114. Seth P, Diaz F, Tao-Cheng JH, Major EO. JC virus induces nonapoptotic cell death of human central nervous system progenitor cell-derived astrocytes. J Virol. 2004;78:4884–4891. doi: 10.1128/JVI.78.9.4884-4891.2004. [PMC free article] [PubMed] [Cross Ref]
115. Shintaku M, Matsumoto R, Sawa H, Nagashima K. Infection with JC virus and possible dysplastic ganglion-like transformation of the cerebral cortical neurons in a case of progressive multifocal leukoencephalopathy. J Neuropathol Exp Neurol. 2000;59:921–929. [PubMed]
116. Shishido-Hara Y, Hara Y, Larson T, Yasui K, Nagashima K, Stoner GL. Analysis of capsid formation of human polyomavirus JC (Tokyo-1 strain) by a eukaryotic expression system: splicing of late RNAs, translation and nuclear transport of major capsid protein VP1, and capsid assembly. J Virol. 2000;74:1840–1853. doi: 10.1128/JVI.74.4.1840-1853.2000. [PMC free article] [PubMed] [Cross Ref]
117. Shishido-Hara Y, Higuchi K, Ohara S, Duyckaerts C, Hauw JJ, Uchihara T. Promyelocytic leukemia nuclear bodies provide a scaffold for human polyomavirus JC replication and are disrupted after development of viral inclusions in progressive multifocal leukoencephalopathy. J Neuropathol Exp Neurol. 2008;67:299–308. doi: 10.1097/NEN.0b013e31816a1dd3. [PubMed] [Cross Ref]
118. Shishido-Hara Y, Ichinose S, Higuchi K, Hara Y, Yasui K. Major and minor capsid proteins of human polyomavirus JC cooperatively accumulate to nuclear domain 10 for assembly into virions. J Virol. 2004;78:9890–9903. doi: 10.1128/JVI.78.18.9890-9903.2004. [PMC free article] [PubMed] [Cross Ref]
119. Shishido Y, Nukuzuma S, Mukaigawa J, Morikawa S, Yasui K, Nagashima K. Assembly of JC virus-like particles in COS7 cells. J Med Virol. 1997;51:265–272. doi: 10.1002/(SICI)1096-9071(199704)51:4<265::AID-JMV2>3.0.CO;2-3. [PubMed] [Cross Ref]
120. Shitrit D, Lev N, Bar-Gil-Shitrit A, Kramer MR. Progressive multifocal leukoencephalopathy in transplant recipients. Transpl Int. 2005;17:658–665. doi: 10.1007/s00147-004-0779-3. [PubMed] [Cross Ref]
121. Silverman L, Rubinstein LJ. Electron microscopic observations on a case of progressive multifocal leukoencephalopathy. Acta Neuropathol. 1965;5:215–224. doi: 10.1007/BF00686519. [PubMed] [Cross Ref]
122. Sisodia SS. Nuclear inclusions in glutamine repeat disorders: are they pernicious, coincidental, or beneficial? Cell. 1998;95:1–4. doi: 10.1016/S0092-8674(00)81743-2. [PubMed] [Cross Ref]
123. Skinner PJ, Koshy BT, Cummings CJ, et al. Ataxin-1 with an expanded glutamine tract alters nuclear matrix-associated structures. Nature. 1997;389:971–974. doi: 10.1038/40153. [PubMed] [Cross Ref]
124. Sock E, Renner K, Feist D, Leger H, Wegner M. Functional comparison of PML-type and archetype strains of JC virus. J Virol. 1996;70:1512–1520. [PMC free article] [PubMed]
125. Sun Y, Durrin LK, Krontiris TG. Specific interaction of PML bodies with the TP53 locus in Jurkat interphase nuclei. Genomics. 2003;82:250–252. doi: 10.1016/S0888-7543(03)00075-2. [PubMed] [Cross Ref]
126. Suzuki S, Sawa H, Komagome R, et al. Broad distribution of the JC virus receptor contrasts with a marked cellular restriction of virus replication. Virology. 2001;286:100–112. doi: 10.1006/viro.2001.0972. [PubMed] [Cross Ref]
127. Sweeney BJ, Manji H, Miller RF, Harrison MJ, Gray F, Scaravilli F. Cortical and subcortical JC virus infection: two unusual cases of AIDS associated progressive multifocal leukoencephalopathy. J Neurol Neurosurg Psychiatry. 1994;57:994–997. doi: 10.1136/jnnp.57.8.994. [PMC free article] [PubMed] [Cross Ref]
128. Takahashi J, Fujigasaki H, Iwabuchi K, et al. PML nuclear bodies and neuronal intranuclear inclusion in polyglutamine diseases. Neurobiol Dis. 2003;13:230–237. doi: 10.1016/S0969-9961(03)00080-9. [PubMed] [Cross Ref]
129. Takahashi J, Fujigasaki H, Zander C, et al. Two populations of neuronal intranuclear inclusions in SCA7 differ in size and promyelocytic leukaemia protein content. Brain. 2002;125:1534–1543. doi: 10.1093/brain/awf154. [PubMed] [Cross Ref]
130. Tan CS, Dezube BJ, Bhargava P, et al. Detection of JC virus DNA and proteins in the bone marrow of HIV-positive and HIV-negative patients: implications for viral latency and neurotropic transformation. J Infect Dis. 2009;199:881–888. doi: 10.1086/597117. [PMC free article] [PubMed] [Cross Ref]
131. Tavalai N, Stamminger T. New insights into the role of the subnuclear structure ND10 for viral infection. Biochim Biophys Acta. 2008;1783:2207–2221. doi: 10.1016/j.bbamcr.2008.08.004. [PubMed] [Cross Ref]
132. Terris B, Baldin V, Dubois S, et al. PML nuclear bodies are general targets for inflammation and cell proliferation. Cancer Res. 1995;55:1590–1597. [PubMed]
133. Tornatore C, Berger JR, Houff SA, et al. Detection of JC virus DNA in peripheral lymphocytes from patients with and without progressive multifocal leukoencephalopathy. Ann Neurol. 1992;31:454–462. doi: 10.1002/ana.410310426. [PubMed] [Cross Ref]
134. Trowbridge PW, Frisque RJ. Identification of three new JC virus proteins generated by alternative splicing of the early viral mRNA. J Neurovirol. 1995;1:195–206. doi: 10.3109/13550289509113966. [PubMed] [Cross Ref]
135. Assche G, Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med. 2005;353:362–368. doi: 10.1056/NEJMoa051586. [PubMed] [Cross Ref]
136. Vendrely A, Bienvenu B, Gasnault J, Thiebault JB, Salmon D, Gray F. Fulminant inflammatory leukoencephalopathy associated with HAART-induced immune restoration in AIDS-related progressive multifocal leukoencephalopathy. Acta Neuropathol. 2005;109:449–455. doi: 10.1007/s00401-005-0983-y. [PubMed] [Cross Ref]
137. Walker DL, Padgett BL, ZuRhein GM, Albert AE, Marsh RF. Human papovavirus (JC): induction of brain tumors in hamsters. Science. 1973;181:674–676. doi: 10.1126/science.181.4100.674. [PubMed] [Cross Ref]
138. Weggen S, Bayer TA, Deimling A, et al. Low frequency of SV40, JC and BK polyomavirus sequences in human medulloblastomas, meningiomas and ependymomas. Brain Pathol. 2000;10:85–92. doi: 10.1111/j.1750-3639.2000.tb00245.x. [PubMed] [Cross Ref]
139. Wei G, Liu CK, Atwood WJ. JC virus binds to primary human glial cells, tonsillar stromal cells, and B-lymphocytes, but not to T lymphocytes. J Neurovirol. 2000;6:127–136. doi: 10.3109/13550280009013156. [PubMed] [Cross Ref]
140. Weidenheim KM, Nelson SJ, Kure K, Harris C, Biempica L, Dickson DW. Unusual patterns of Histoplasma capsulatum meningitis and progressive multifocal leukoencephalopathy in a patient with the acquired immunodeficiency virus. Hum Pathol. 1992;23:581–586. doi: 10.1016/0046-8177(92)90137-R. [PubMed] [Cross Ref]
141. White FA, III, Ishaq M, Stoner GL, Frisque RJ. JC virus DNA is present in many human brain samples from patients without progressive multifocal leukoencephalopathy. J Virol. 1992;66:5726–5734. [PMC free article] [PubMed]
142. White MK, Gordon J, Reiss K, et al. Human polyomaviruses and brain tumors. Brain Res Brain Res Rev. 2005;50:69–85. doi: 10.1016/j.brainresrev.2005.04.007. [PubMed] [Cross Ref]
143. Wuthrich C, Cheng YM, Joseph JT, et al. Frequent infection of cerebellar granule cell neurons by polyomavirus JC in progressive multifocal leukoencephalopathy. J Neuropathol Exp Neurol. 2009;68:15–25. doi: 10.1097/NEN.0b013e3181912570. [PMC free article] [PubMed] [Cross Ref]
144. Wuthrich C, Dang X, Westmoreland S, et al. Fulminant JC virus encephalopathy with productive infection of cortical pyramidal neurons. Ann Neurol. 2009;65:742–748. doi: 10.1002/ana.21619. [PMC free article] [PubMed] [Cross Ref]
145. Yang B, Prayson RA. Expression of Bax, Bcl-2, and P53 in progressive multifocal leukoencephalopathy. Mod Pathol. 2000;13:1115–1120. doi: 10.1038/modpathol.3880206. [PubMed] [Cross Ref]
146. Yogo Y, Kitamura T, Sugimoto C, et al. Sequence rearrangement in JC virus DNAs molecularly cloned from immunosuppressed renal transplant patients. J Virol. 1991;65:2422–2428. [PMC free article] [PubMed]
147. Yogo Y, Kitamura T, Sugimoto C, et al. Isolation of a possible archetypal JC virus DNA sequence from nonimmunocompromised individuals. J Virol. 1990;64:3139–3143. [PMC free article] [PubMed]
148. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med. 2006;354:924–933. doi: 10.1056/NEJMoa054693. [PMC free article] [PubMed] [Cross Ref]
149. Zheng H, Abdel Aziz HO, Nakanishi Y, et al. Oncogenic role of JC virus in lung cancer. J Pathol. 2007;212:306–315. doi: 10.1002/path.2188. [PubMed] [Cross Ref]
150. Zurhein G, Chou SM. Particles resembling papova viruses in human cerebral demyelinating disease. Science. 1965;148:1477–1479. doi: 10.1126/science.148.3676.1477. [PubMed] [Cross Ref]

Articles from Springer Open Choice are provided here courtesy of Springer

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...